Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Still a Buy?

Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $15.43 and last traded at $15.38, with a volume of 1228561 shares traded. The stock had previously closed at $15.32.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.6 %

The stock has a market capitalization of $45.69 billion, a P/E ratio of 35.90, a PEG ratio of 0.24 and a beta of 0.26. The stock's fifty day moving average is $14.87 and its two-hundred day moving average is $14.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. FNY Investment Advisers LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter worth $37,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $40,000. Farther Finance Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at approximately $52,000. Finally, Cromwell Holdings LLC purchased a new stake in Takeda Pharmaceutical in the 4th quarter worth approximately $61,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.